Loss of tumor suppressor gene expression in high-grade but not low- grade non-Hodgkin's lymphomas

American Journal of Clinical Pathology

Volumn 109, Issue 6, 1998, Pages 669-674

  Geradts, Joseph ^a   Andriko, Joann W ^b   Abbondanzo, Susan L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Cell cycle checkpoint abrogation; Immunohistochemistry; Lymphomas; P16; Paraffin sections; Retinoblastoma protein

Indexed keywords

PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GRADING; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031835211     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/109.6.669     Document Type: Article

References (33)

1. Horowitz JM, Park S, Bogenman E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA. 1990; 87:2775-2779.
2. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
3. Bartkova J, Lukas J, Müller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994;57:353-361.
4. Schmidt EE, Ichimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994;54:6321-6324.
5. Kamb A. Cell cycle regulators and cancer. Trends Genet. 1995;11:136-140.
6. Martínez JC, Piris MA, Sánchez-Beato M, et al. Retinoblastoma (Rb) gene product expression in lymphomas: correlation with Ki67 growth fraction. J Pathol. 1993;169:405-412.
7. Kornblau SM, Chen N, del Giglio A, et al. Retinoblastoma protein is frequently altered in chronic lymphocytic leukemia. Cancer Res. 1994;54:242-246.
8. Weide R, Tiemann M, Pflüger KH. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia. 1994;8:97-101.
9. Newcomb EW, Thomas A, Selkirk A, et al. Frequent homozygous deletions of D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res. 1995; 55:2044-2047.
10. Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Am J Pathol. 1996;148:1591-1600.
11. Nguyen PL, Zukerberg LR, Benedict WF, et al. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. Am J Clin Pathol. 1996;105:538-543.
12. Ginsberg AM, Raffeld M, Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood. 1991;77:833-840.
13. Serra A, Gottardi E, Ragione FD, et al. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haemotol. 1995;91:625-629.
14. Iolascon A, Faienza MF, Copolla B, et al. High frequency of homozygous deletions of CDK4I gene in childhood acute lymphoblastic leukaemia. Br J Haematol. 1995;91:647-651.
15. Stranks G, Height SE, Mitchell P, et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood. 1995;85:893-901.
16. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995;55:1436-1440.
17. INK4B in non-Hodgkin's lymphomas. Blood. 1995; 86:1534-1539.
18. Ogawa S, Hangaishi A, Miyawaki S, et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995;86:1548-1556.
19. INK4A) gene in primary B-cell lymphomas. Blood. 1995;86:2724-2731.
20. Koduru PRK, Zariwala M, Soni M, et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood. 1995;86:2900-2905.
21. Kees UR, Ranford PR, Hatzis M. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. Oncogene. 1996;12:2235-2239.
22. Kumanishi T, Zhang S, Ichikawa T, et al. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions. Jpn J Cancer Res. 1996;87:691-695.
23. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832-836.
24. INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
25. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 1995; 55:6006-6011.
26. INK4A expression in resected no-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
27. INK4A expression in human breast cancer. Am J Pathol. 1996;149:1-6.
28. Wen SF, Nodelman M, Nared-Hood K, et al. Retinoblastoma protein monoclonal antibodies with novel characteristics. J Immunol Methods. 1994;169;231-240.
29. Geradts J, Kratzke RA, Crush-Stanton S, et al. Wild type and mutant retinoblastoma protein in paraffin sections. Mod Pathol. 1996;9:339-347.
30. Chaganti SR, Gaidano G, Louie DC, et al. Diffuse large cell lymphomas exhibit frequent deletions in 9p21-22 and 9q31-34 Regions. Genes Chromosomes Cancer. 1995;12:32-36.
31. Zukerberg LR, Yang W, Arnold A, et al. Cyclin D1 expression in non-Hodgkin's lymphomas: detection by immunohistochemistry. Am J Clin Pathol. 1996;103:756-760.
32. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
33. Bartsch D, Shevlin DW, Callery MP, et al. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst. 1996;88:680-681.